Drug-based optical agents: infiltrating clinics at lower risk.
about
Dendritic Polymers for TheranosticsImage-guided cancer surgery using near-infrared fluorescence.Multispectral fluorescence ultramicroscopy: three-dimensional visualization and automatic quantification of tumor morphology, drug penetration, and antiangiogenic treatment responseIncreased precision of orthotopic and metastatic breast cancer surgery guided by matrix metalloproteinase-activatable near-infrared fluorescence probesFluorocoxib A loaded nanoparticles enable targeted visualization of cyclooxygenase-2 in inflammation and cancerNear-infrared fluorescence imaging of both colorectal cancer and ureters using a low-dose integrin targeted probe.Intraoperative imaging-guided cancer surgery: from current fluorescence molecular imaging methods to future multi-modality imaging technology.Current frontiers in clinical research application of MALDI imaging mass spectrometry.Preclinical evaluation of a novel CEA-targeting near-infrared fluorescent tracer delineating colorectal and pancreatic tumors.Towards clinically translatable NIR fluorescence molecular guidance for colonoscopy.Clinically compatible flexible wide-field multi-color fluorescence endoscopy with a porcine colon modelPharmacokinetic and Biodistribution Assessment of a Near Infrared-Labeled PSMA-Specific Small Molecule in Tumor-Bearing Mice.Antibody-based imaging strategies for cancer.Regulatory Aspects of Optical Methods and Exogenous Targets for Cancer Detection.Identification of the optimal therapeutic antibody for fluorescent imaging of cutaneous squamous cell carcinoma.Improved decision making for prioritizing tumor targeting antibodies in human xenografts: Utility of fluorescence imaging to verify tumor target expression, antibody binding and optimization of dosage and application scheduleSafety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers.
P2860
Q26746182-6E02EC73-0F18-46F9-947E-2BEBD15070CDQ30432014-456F9D47-2BF9-436F-AA5C-F5E720E2DBA3Q30571893-B0B277EA-F03D-4805-8EB1-EA413E24FDF5Q30665907-7C55E28D-F974-423E-9338-4B138A70ECCEQ30743369-30111A73-12E6-4105-94DD-2EDD7A7B3372Q34028690-2E587C6A-76C9-43D7-9077-372DFB8F197CQ34195631-E4C7906A-1CA8-4B69-9E86-2ABF966F1C48Q34777079-67471CB7-5DFA-446E-ABF8-F8BA91748551Q37366754-093E8537-8315-49C5-91EF-BC510447BAD0Q37476924-FC0C0357-7ABD-4EDA-8A89-BE9A7BEB2CDAQ37671941-ACBC6D31-E731-48EA-A4AF-072DE7ECA863Q37719087-B37CB63F-973F-48CB-BC4B-B0D9B01B9050Q38218986-868FD345-0440-476F-8F9D-3E076D4403B5Q38827744-4454C41B-08E8-4097-BA1D-A2C0DEA56E14Q39214232-D10D49F0-09A2-4229-ABBB-4E3FFDE1C82DQ39358414-7D5F32C1-DF63-40F6-8EDF-D71D7A8A25E4Q52714380-9E5BF179-3677-467C-8106-A7ECCB5AE8D0
P2860
Drug-based optical agents: infiltrating clinics at lower risk.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Drug-based optical agents: infiltrating clinics at lower risk.
@en
type
label
Drug-based optical agents: infiltrating clinics at lower risk.
@en
prefLabel
Drug-based optical agents: infiltrating clinics at lower risk.
@en
P2093
P2860
P1476
Drug-based optical agents: infiltrating clinics at lower risk.
@en
P2093
Gooitzen M van Dam
Michael Dobosz
Werner Scheuer
P2860
P304
P356
10.1126/SCITRANSLMED.3003572
P407
P577
2012-05-01T00:00:00Z